What does Oaktree Acquisition Corp. III Life Sciences do?
Oaktree Acquisition Corp. III Life Sciences, trading on Nasdaq under the Class A share ticker OACC, is a special purpose acquisition company rather than an operating life-sciences business. It was incorporated in the Cayman Islands on June 28, 2024 to identify, negotiate and complete a merger, share exchange, asset acquisition, share purchase, reorganization or similar transaction. Its legal and financial structure is described in the company’s final IPO prospectus.
The name “Life Sciences” signals the intended search field, but it does not mean OACC currently sells medicines, devices or services. As of March 31, 2026, it had not selected a target and had not commenced operating activities. Its economic purpose is to convert a pool of publicly raised cash, sponsor expertise and a listed acquisition vehicle into ownership of a future operating company. Until a transaction closes, nearly all analytical attention belongs on trust assets, redemption rights, sponsor incentives, transaction timing and the quality of any eventual target.
Why is this not a normal company analysis?
A normal company is valued from revenue growth, margins, capital intensity and free cash flow. OACC has no operating revenue and no commercial segment. Its reported net income comes mainly from interest on the trust account, while operating cash is consumed by legal, diligence, listing and administrative costs. Therefore, the current security resembles a time-limited acquisition option supported by redeemable trust value, not a claim on an established life-sciences franchise.
How does OACC make money?
Before a business combination, OACC has no operating business model. The company earns non-operating interest on cash and U.S. government-oriented investments held in trust. That interest generally increases the redemption value per public share, subject to permitted withdrawals for taxes and limited working-capital needs. The company’s latest Form 10-Q for the quarter ended March 31, 2026 reported $1.851 million of trust interest and no operating revenue.
The trust account is the current economic engine
The distinction is crucial. Trust cash is not ordinary corporate liquidity that management can freely spend. It is ring-fenced for a business combination, shareholder redemptions and specified permitted withdrawals. Outside-trust cash pays the recurring costs of being a public shell and evaluating targets. If that outside pool becomes insufficient, the sponsor or affiliates may provide working-capital loans, but additional financing can introduce complexity and potential dilution.
The post-merger model is still unknown
After a successful transaction, OACC shareholders would own shares in a combined operating company. At that point, the revenue model could involve drug sales, device revenue, diagnostics, royalties, reimbursement or specialized healthcare services. None of those economics can be analyzed responsibly until a definitive agreement identifies a target and transaction terms. For now, the “revenue stream” is trust interest, and the strategic asset is the sponsor’s ability to source and underwrite a life-sciences deal.
What did OACC’s latest reported quarter show?
The quarter ended March 31, 2026 reinforces the pre-deal character of the company. OACC generated no revenue, recorded $456,538 of general and administrative expense, earned $1.851 million of trust interest and reported $1.394 million of net income. The apparent profit does not indicate operating success; it is primarily the accounting result of interest earned on capital that is largely redeemable by public shareholders.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Operating revenue | $0 | $0 | No target company had been acquired. |
| General and administrative expense | $456,538 | $444,802 | Public-company and transaction-search costs remained modest but recurring. |
| Trust interest | $1,850,659 | $2,103,593 | Lower than the prior-year quarter, but still the dominant income source. |
| Net income | $1,394,121 | $1,658,791 | Accounting profit was interest-driven, not operational. |
| Basic and diluted EPS | $0.06 | $0.07 | Shared pro rata across redeemable and non-redeemable ordinary shares. |
What changed on the balance sheet?
Trust assets increased from $201.564 million at December 31, 2025 to $203.414 million at March 31, 2026, closely matching the quarter’s trust interest. Outside-trust cash declined from $1.435 million to $1.277 million. Current liabilities rose to $1.624 million, including $751,463 of accounts payable and accrued expenses, $860,857 due to a related party and an $11,824 related-party promissory note. Deferred legal fees were $299,088, while deferred underwriting fees remained $6.720 million and become payable only if a business combination closes.
Which financial metrics matter most for a pre-deal SPAC?
Revenue and conventional margins are not useful at this stage. The most informative indicators are trust value, redemption value per share, outside-trust cash, operating cash burn, deferred transaction costs, sponsor funding, the time remaining before liquidation and the ownership split between public investors and the sponsor.
| KPI | Latest disclosed value | Why it matters |
|---|---|---|
| Trust account | $203.414M at March 31, 2026 | Supports redemptions and transaction funding. |
| Redeemable Class A shares | 19.199M shares | Defines the public capital base exposed to redemption. |
| Implied trust value per redeemable share | About $10.60 at March 31, 2026 | Computed from trust cash divided by redeemable shares; a useful reference before taxes and permitted withdrawals. |
| Outside-trust cash | $1.277M at March 31, 2026 | Funds diligence, advisers and ongoing overhead. |
| Operating cash burn | $158,035 in Q1 2026 | Shows the rate at which unrestricted liquidity is consumed. |
| Combination deadline | October 25, 2026 | Failure to close or extend would lead toward liquidation. |
Why trust interest is not free cash flow
OACC reported positive net income but negative operating cash flow in Q1 2026. The reconciliation explains the difference: $1.851 million of interest increased accounting income and trust value, but it did not provide ordinary unrestricted cash for operations. Free cash flow is therefore not meaningful in the conventional sense. The economically relevant cash burn is the decrease in funds outside the trust, adjusted for related-party balances and permitted withdrawals.
What did the 2025 annual report add?
The 2025 Form 10-K reported $8.485 million of trust interest, $1.196 million of operating loss, $7.289 million of net income and $422,080 of operating cash used during 2025. Year-end trust cash was $201.564 million, outside-trust cash was $1.435 million and the redemption value was $10.50 per public share. These figures show that the vehicle was adequately capitalized for a search, but also that the liquidation deadline had become the dominant constraint.
What strategic history shaped OACC?
OACC’s short history is best understood as a sequence of capital formation, listing and governance events rather than product milestones. Each step affects control, deadline risk or the resources available for a transaction.
-
June 2024The company was incorporated as a Cayman Islands exempted company, establishing the legal shell for a future business combination.
-
October 2024The IPO sold 17.5 million units at $10 each; a partial over-allotment added 1,699,029 units, bringing public units to 19,199,029.
-
October 2024The sponsor purchased 583,981 private placement units, supplying additional transaction capital and creating sponsor exposure through shares and warrants.
-
January 2025John Frank left the board; Aman Kumar became chair and CEO Zaid Pardesi joined the board, concentrating transaction leadership around the active sponsor team.
-
June 2025Courtney Conigliaro resigned as CFO and Thomas Sweeney was appointed, beginning a period of finance-leadership turnover.
-
October 2025Thomas Sweeney resigned and George A. Martinez became CFO; the change mattered because financial reporting and transaction execution are central functions in a SPAC.
-
March 2026The annual report explicitly raised substantial doubt about going concern because the company must complete a deal by October 25, 2026 or proceed toward liquidation.
Why sponsor lineage matters
The company’s strategic proposition rests on access to Oaktree’s broader investment network and the management team’s life-sciences relationships. Oaktree describes its platform as focused on risk control and value-oriented investing on its official website. That institutional association may help source complex or capital-constrained targets, but it does not guarantee that a suitable public-market transaction will emerge within the remaining period.
Who controls OACC, and why does ownership matter?
OACC has two principal economic constituencies: public Class A shareholders with redemption rights and a sponsor holding founder shares plus private placement securities. At December 31, 2025, 19,199,029 Class A shares were subject to possible redemption. The sponsor, Oaktree Acquisition Holdings III LS, LLC, held 4,799,758 Class B founder shares and 583,981 private placement units, each containing one private placement share and one-fifth of one warrant.
| Holder or class | Position | Rights and influence | Why it matters |
|---|---|---|---|
| Public Class A holders | 19,199,029 redeemable shares | Vote on a proposed transaction and may redeem for a pro rata trust amount. | High redemptions can reduce cash available to the combined company. |
| Sponsor founder shares | 4,799,758 Class B shares | Convert one-for-one into Class A shares, subject to adjustment; no trust liquidation rights. | Creates substantial upside if a deal closes and a loss if the SPAC liquidates. |
| Sponsor private placement units | 583,981 units | Include 583,981 shares and 116,796 warrants. | Adds sponsor capital but also potential post-deal dilution. |
| Goldman Sachs entities | 6.2% of Class A in a 2026 Schedule 13G | Institutional economic ownership; generally not sponsor control. | Illustrates the arbitrage and institutional investor base common in pre-deal SPACs. |
The sponsor incentive is powerful but not perfectly aligned
The sponsor’s founder shares were acquired for nominal consideration and become valuable if a transaction closes and the post-merger shares retain value. If no deal closes, the founder shares and private warrants generally expire worthless. This creates motivation to complete a transaction, but public shareholders may prefer liquidation or redemption to a weak deal. The company itself warns that the sponsor may have interests that differ from public investors. A 2026 Schedule 13G also shows that institutional ownership can be meaningful even before a target is announced.
What gives OACC a competitive advantage in life-sciences dealmaking?
A SPAC has no product moat before a transaction. Its potential advantage lies in sponsor reputation, sourcing access, underwriting discipline, board credibility and the ability to assemble financing. OACC’s stated focus includes biopharmaceuticals, medical devices, diagnostics and specialized healthcare services in North America and Europe. The sector can suit a sponsor with experience evaluating intellectual property, clinical risk, reimbursement, commercialization and capital needs.
Where the advantage is limited
Competition for attractive targets is intense. OACC competes not only with other SPACs but also with strategic acquirers, private-equity funds, venture investors and traditional IPO routes. A target with strong prospects may demand a higher valuation or more favorable governance terms. Conversely, a company willing to accept a SPAC merger may have financing urgency, clinical uncertainty or limited access to conventional public markets. The sponsor’s advantage therefore depends on finding a business where complexity creates opportunity rather than hidden impairment.
| Competing route | Strength versus OACC | OACC’s possible response |
|---|---|---|
| Traditional IPO | Broader price discovery and no sponsor promote. | Offer greater timetable certainty and negotiated valuation. |
| Strategic buyer | Can pay for operating synergies and provide commercial infrastructure. | Offer continued independence and public equity upside. |
| Private equity or growth capital | Can keep the target private and reduce public-market scrutiny. | Provide immediate listing and access to public capital markets. |
| Other healthcare SPACs | May have more time, a larger trust or stronger sector-specific operators. | Differentiate through Oaktree relationships and disciplined structuring. |
What risks could change OACC’s outcome?
The leading risk is binary: OACC must complete a business combination by October 25, 2026 unless shareholders approve an extension. The auditor’s 2025 report stated that the mandatory liquidation date raises substantial doubt about the company’s ability to continue as a going concern. Liquidation would return the trust to public shareholders, subject to permitted deductions, while founder shares and private warrants would likely become worthless.
Why a successful deal can still produce a weak investment
Completion alone is not success. A transaction can destroy value if the target’s forecasts are too aggressive, the capital structure is overleveraged, redemptions are heavy or the sponsor promote is large relative to cash delivered. Life-sciences targets add special risks: products may be pre-revenue, clinical milestones may fail, regulatory approvals may be delayed and future equity raises may be unavoidable. Investors must analyze the eventual merger proxy and target financials as a new case rather than relying on the current trust-backed structure.
Governance turnover deserves attention
OACC experienced a board-chair change in January 2025 and two CFO transitions during 2025. The company disclosed that the departures were not due to disagreements, but repeated finance-leadership changes can still matter in a transaction vehicle because accounting, controls, merger documentation and financing execution are central to the process. The relevant filings include the January 2025 board-change filing, the June 2025 CFO filing and the October 2025 CFO filing.
Why does OACC matter for valuation?
A pre-deal OACC valuation is anchored less by an enterprise-value multiple than by the relationship among market price, trust value, redemption rights, warrant value, transaction probability and time. The Class A share can trade near trust value because holders may redeem in connection with a proposed transaction. However, the eventual post-merger value may move far away from that anchor once redemption protection ends.
| Valuation driver | Current anchor | What changes after a deal |
|---|---|---|
| Trust value | About $10.60 per redeemable share at March 31, 2026 | Becomes operating-company cash, transaction consideration or redemption proceeds. |
| Time value | Deadline to October 25, 2026 | Replaced by execution and operating risks of the acquired business. |
| Warrant optionality | $11.50 exercise price per whole warrant | Depends on post-merger share performance and redemption provisions. |
| Dilution | Founder shares and private placement securities outstanding | May expand through PIPE financing, earnouts, debt conversion or additional warrants. |
| Operating value | Not yet determinable | Requires a DCF built from target revenue, margins, reinvestment, dilution and probability-adjusted risk. |
How should a future DCF be built?
Once a target is announced, analysts should separate the transaction from the business. First calculate cash delivered after redemptions, fees and financing. Then determine fully diluted shares including founder shares, public and private warrants, earnouts and PIPE securities. Only after reconciling that capitalization should a target DCF model revenue, gross margin, operating expense, taxes, capital needs and terminal risk. For a biotech target, probability-adjusted clinical cash flows may be essential; for devices or diagnostics, adoption, reimbursement and commercial margins may dominate.
What is the key takeaway from OACC analysis?
OACC is best viewed as a listed acquisition vehicle backed by roughly $203.4 million of trust assets as of March 31, 2026, not as an operating life-sciences company. Its current reported income is generated by interest on the trust, while unrestricted cash funds the search process. The sponsor’s institutional network and sector focus may help identify a complex healthcare opportunity, but the vehicle’s value ultimately depends on target quality, transaction terms, redemption levels, dilution and timing.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.